Back to News
Market Impact: 0.15
Bexorg Awarded Up to $28.3 Million from ARPA-H to Advance Human Brain Translational Pharmacology for CNS Drug Development
Source: GlobeNewswire
Healthcare & BiotechTechnology & Innovation
A three-phase, 36-month award aims to extend BrainEx perfusion from 24 hours to as long as two weeks. The longer duration is intended to enable longitudinal studies of human brain biology and therapeutic responses; the article fragment provides no award amount or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- Elon Musk blames Indian 'oligarchs' for stalling Starlink launch
- FCC to vote on auctioning 25MHz of 'prime spectrum' in move that could benefit Amazon, SpaceX
- Microsoft shows off new Windows software, revamped for agentic AI
- Wolfspeed secures $1.5 billion conditional loan commitment from US defense department
- Microsoft to sell $2,599 Surface Laptop Ultra containing Nvidia AI chip
- New data strengthens our faith in a TJX comeback. Plus, the Nvidia-Microsoft PC is here
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AlphaSense vs Hebbia vs AllMind: Choose by Workflow
- AllMind Discusses Ontario's AI Economy with Minister Stephen Crawford and Supply Ontario CEO James Wallace